The European Medicines Agency and national agency heads are working together on the availability of medicines and big data in medicines evaluation, the EMA is extending a multinational approach to drug assessment that is reducing the agency’s reliance on UK experts in preparation for Brexit, and new guidance is planned by the EMA on data integrity. These are just some of the many regulatory developments that EMA deputy executive director Noel Wathion covered in his presentation at the Annual European Medicines Agency Review of the Year and Outlook for 2017 conference, which took place recently in London.
The Pink Sheet will report in more detail on some of these topics over the coming weeks. In the meantime,...